bladder cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathological or histological diagnosis of primary non-muscle invasive bladder urothelial carcinoma (TaTisT1); 2. Imaging examinations showed the bladder muscle has not been affected, no lymph node metastasis or distant metastasis; 3. Patients who agree to TURBT surgery, and will be effected to the postoperative follow-up treatment such as conventional infusion after the operation; 4. Function of main organs (heart, liver, lung, kidney) should be normal, PS score 0-2; 5. Bladder capacity= 200ml.
Exclusion criteria
Exclusion criteria: 1. Find distant metastasis ,infiltration of the surrounding organs or relapse before operation.Metastatic bladder cancer or other cancers involve the bladder; 2. Received chemotherapy or BCG perfusion therapy in the nearly 3 months; 3. Patients who can not tolerate the serious side effects during the bladder perfusion treatment process (bladder irritation and other symptoms); 4. Patients during pregnancy ,critical care patients and patients who have other cases of surgical contraindications.Such as serious cardiovascular disease,coagulation abnormalities,non-transitional epithelial tumors( such as adenocarcinoma and squamous cell carcinoma),acute cystitis,can not be supine because of spinal deformity,untreated urethral stricture.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The residual rate of tumor in the second operation of the two surgical methods; | — |
Secondary
| Measure | Time frame |
|---|---|
| Perioperative complications associated with two surgical methods;1 year, 2 years, 3 years of tumor recurrence rate and progression rate;5-year recurrence-free survival rate and progression-free survival rate;The length of operation, catheter retention and hospitalization; | — |
Countries
China
Contacts
Department of Urology Center, Shanghai General Hospital, Shanghai Jiaotong University